Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Copeland

Showing results (331-340 of 449) with videos related to

Pageof 45
Sort By:
Gene Therapy|June 13, 2000
Pretreatment with cationic lipid-mediated transfer of the Na+K+-ATPase pump in a mouse model in vivo augments resolution of high permeability pulmonary oedemaM Stern, K Ulrich, C Robinson, et al.
Circulation|November 1, 1990
Internal mammary artery and saphenous vein graft patency. Effects of aspirinS Goldman, J Copeland, T Moritz, et al.
The New England Journal of Medicine|January 6, 2006
Intraperitoneal cisplatin and paclitaxel in ovarian cancerDeborah K Armstrong, Brian Bundy, Lari Wenzel, et al.
Gynecologic Oncology|October 3, 2008
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancerDebra L Richardson, Floor J Backes, Leigh G Seamon, et al.
Gynecologic Oncology|February 16, 2010
Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancerKimberly E Resnick, Wendy L Frankel, Carl D Morrison, et al.
Scientific Reports|September 2, 2017
Impact of Immunosuppression on the Metagenomic Composition of the Intestinal Microbiome: a Systems Biology Approach to Post-Transplant DiabetesM Bhat, E Pasini, J Copeland, et al.
Gynecologic Oncology|April 13, 2010
Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?D L Richardson, F J Backes, J D Hurt, et al.
Gynecologic Oncology|November 26, 2016
Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?Blair Smith, Georgia A McCann, Gary Phillips, et al.
Cancer|September 15, 1987
Prognostic factors in stage II endometrial carcinomaD M Larson, L J Copeland, H S Gallager, et al.
Gynecologic Oncology Reports|April 17, 2025
Assessment of readability of informed consent forms of gynecologic cancer clinical trials: A (Potential) barrier to enrollment?Wafa K Khadraoui, Quinn M Kistenfeger, Molly Herman, et al.
Pageof 45

Showing results (331-340 of 449) with videos related to

Sort By:
Pageof 45
Gene Therapy|June 13, 2000
Pretreatment with cationic lipid-mediated transfer of the Na+K+-ATPase pump in a mouse model in vivo augments resolution of high permeability pulmonary oedemaM Stern, K Ulrich, C Robinson, et al.
Circulation|November 1, 1990
Internal mammary artery and saphenous vein graft patency. Effects of aspirinS Goldman, J Copeland, T Moritz, et al.
The New England Journal of Medicine|January 6, 2006
Intraperitoneal cisplatin and paclitaxel in ovarian cancerDeborah K Armstrong, Brian Bundy, Lari Wenzel, et al.
Gynecologic Oncology|October 3, 2008
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancerDebra L Richardson, Floor J Backes, Leigh G Seamon, et al.
Gynecologic Oncology|February 16, 2010
Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancerKimberly E Resnick, Wendy L Frankel, Carl D Morrison, et al.
Scientific Reports|September 2, 2017
Impact of Immunosuppression on the Metagenomic Composition of the Intestinal Microbiome: a Systems Biology Approach to Post-Transplant DiabetesM Bhat, E Pasini, J Copeland, et al.
Gynecologic Oncology|April 13, 2010
Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?D L Richardson, F J Backes, J D Hurt, et al.
Gynecologic Oncology|November 26, 2016
Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?Blair Smith, Georgia A McCann, Gary Phillips, et al.
Cancer|September 15, 1987
Prognostic factors in stage II endometrial carcinomaD M Larson, L J Copeland, H S Gallager, et al.
Gynecologic Oncology Reports|April 17, 2025
Assessment of readability of informed consent forms of gynecologic cancer clinical trials: A (Potential) barrier to enrollment?Wafa K Khadraoui, Quinn M Kistenfeger, Molly Herman, et al.
Pageof 45